PMC4112035_01
Negative IHC staining for ER.
40064_2014_1062_Fig1_HTML.jpg
PMC4112035_01_40064_2014_1062_Fig1_HTML.jpg
Fig1
The estrogen receptor (ER) (Figure 1), and progesterone receptor (PR) (Figure 2) status evaluated by IHC were negative and weakly focally positive respectively; however, androgen receptor (AR) (Figure 3) was strongly positive in 90% of cells with +2 level of staining.
Focally positive IHC staining for PR.
40064_2014_1062_Fig2_HTML.jpg
PMC4112035_01_40064_2014_1062_Fig2_HTML.jpg
Fig2
The estrogen receptor (ER) (Figure 1), and progesterone receptor (PR) (Figure 2) status evaluated by IHC were negative and weakly focally positive respectively; however, androgen receptor (AR) (Figure 3) was strongly positive in 90% of cells with +2 level of staining.
Positive IHC staining for AR.
40064_2014_1062_Fig3_HTML.jpg
PMC4112035_01_40064_2014_1062_Fig3_HTML.jpg
Fig3
The estrogen receptor (ER) (Figure 1), and progesterone receptor (PR) (Figure 2) status evaluated by IHC were negative and weakly focally positive respectively; however, androgen receptor (AR) (Figure 3) was strongly positive in 90% of cells with +2 level of staining.
Pulmonary metastasis from SGC before starting bicalutamide.
40064_2014_1062_Fig4_HTML.jpg
PMC4112035_01_40064_2014_1062_Fig4_HTML.jpg
Fig4
PET-CT after three months indicated a complete response in the pulmonary nodules (Figures 4 and 5).
Complete response in the pulmonary metastasis from SGC, 3 months after starting bicalutamide.
40064_2014_1062_Fig5_HTML.jpg
PMC4112035_01_40064_2014_1062_Fig5_HTML.jpg
Fig5
PET-CT after three months indicated a complete response in the pulmonary nodules (Figures 4 and 5).